New data for KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Tarcocimab tedromer (KSI-301) 5mg: outcomes of the Phase 3 GLOW1 Study in patients with non-proliferative diabetic retinopathy.
